Difference between revisions of "Alemtuzumab (Campath)"
m |
|||
| Line 15: | Line 15: | ||
*[[Myelodysplastic syndrome]] | *[[Myelodysplastic syndrome]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| + | *[[T-cell prolymphocytic leukemia]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
| Line 47: | Line 48: | ||
[[Category:Myelodysplastic syndrome medications]] | [[Category:Myelodysplastic syndrome medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | [[Category:T-cell prolymphocytic leukemia medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:REMS program]] | [[Category:REMS program]] | ||
[[Category:FDA approved in 2001]] | [[Category:FDA approved in 2001]] | ||
Revision as of 01:13, 20 May 2021
General information
Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.[1][2][3]
Route: IV
Extravasation: neutral
- Use of alemtuzumab (Lemtrada) requires participation in the Lemtrada REMS program.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adult T-cell leukemia-lymphoma
- Autoimmune cytopenia
- Chronic lymphocytic leukemia
- Cutaneous T-cell lymphoma
- Hypereosinophilic syndrome
- Myelodysplastic syndrome
- Peripheral T-cell lymphoma
- T-cell prolymphocytic leukemia
- Waldenström macroglobulinemia
Patient drug information
- Alemtuzumab (Campath) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found at the end of page 2 of the Alemtuzumab (Campath) package insert
- Alemtuzumab (Campath) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 5/7/2001: Initial approval for the treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.[6]
- 9/19/2007: Indication expanded to include use as a single agent for treatment of B-cell chronic lymphocytic leukemia (B-CLL)
- October 2012: Genzyme withdraws drug from USA and EU (still available for B-CLL patients, however). See Lancet editorial.[7]
Also known as
- Code name: LDP03
- Brand names: Campath, Campath-1H, Lemtrada, Mabcampath
References
- ↑ 1.0 1.1 Alemtuzumab (Campath) package insert
- ↑ Alemtuzumab (Campath) package insert (locally hosted backup)
- ↑ Campath manufacturer's website
- ↑ Alemtuzumab (Campath) patient drug information (Chemocare)
- ↑ Alemtuzumab (Campath) patient drug information (UpToDate)
- ↑ FDA approval letter dated May 7th, 2001
- ↑ Alemtuzumab for multiple sclerosis
- Drugs
- Intravenous medications
- Neutral
- Anti-CD52 antibodies
- Adult T-cell leukemia-lymphoma medications
- Autoimmune cytopenia medications
- Chronic lymphocytic leukemia medications
- Cutaneous T-cell lymphoma medications
- Hypereosinophilic syndrome medications
- Myelodysplastic syndrome medications
- Peripheral T-cell lymphoma medications
- T-cell prolymphocytic leukemia medications
- Waldenström macroglobulinemia medications
- REMS program
- FDA approved in 2001